The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer.

Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

Publication: 2020- : London : Elsevier
Original Publication: Dordrecht ; Boston : Kluwer Academic Publishers, c1990-

Urinary Bladder Neoplasms*/pathology ; Urinary Bladder Neoplasms*/drug therapy ; Urinary Bladder Neoplasms*/immunology ; Urinary Bladder Neoplasms*/genetics ; Urinary Bladder Neoplasms*/metabolism ; Antigens, Surface*; Humans ; Immunoconjugates/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Transitional Cell/drug therapy ; Carcinoma, Transitional Cell/pathology ; Carcinoma, Transitional Cell/immunology ; Carcinoma, Transitional Cell/genetics ; Urologic Neoplasms/immunology ; Urologic Neoplasms/pathology ; Urologic Neoplasms/drug therapy ; Urologic Neoplasms/genetics ; Glutamate Carboxypeptidase II/metabolism ; Glutamate Carboxypeptidase II/immunology ; Antigens, Neoplasm/immunology ; Antigens, Neoplasm/genetics

Competing Interests: Disclosure FB: Gilead (lecture fees, congress invitations), Novartis (consulting fees, lecture fees, congress invitations); AdN: Gilead (lecture fees, congress invitations), Daiichi Sankyo (lecture fees, congress invitations), Seagen (consulting fees), Lilly (lecture fees, congress invitations, consulting fees), Novartis (consulting fees, congress invitations), MSD (congress invitations, lecture fees), Pfizer (research grants paid to institution, congress invitations). All other authors have declared no conflicts of interest.

0 (Immunoconjugates)
EC 3.4.17.21 (Glutamate Carboxypeptidase II)
EC 3.4.17.21 (FOLH1 protein, human)
0 (Antigens, Neoplasm)
0 (Antigens, Surface)

Date Created: 20240216 Date Completed: 20240502 Latest Revision: 20240502

20240503

10.1016/j.annonc.2024.02.001

38364991